August 15th, 2011
Bare Metal Stents: The Next New Thing?
Larry Husten, PHD
Although drug-eluting stents (DES) have largely supplanted bare metal stents (BMS) in clinical practice, a new study published in Circulation suggests that using these devices in all patients may represent an inefficient use of healthcare resources. Lakshmi Venkitachalam and colleagues analyzed data from 10,144 PCI patients enrolled in the Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) registry.
Largely in response to concerns about the possible risks associated with DES, the use of DES decreased from 92% to 68% from 2004 to 2007, according to the registry. However, the rates of death and MI did not change over time, although the rate of target lesion revascularization (TLR) increased absolutely by 1% (from 4.1% to 5.1%). Total cardiovascular cost per patient decreased by $401. The authors estimate that the risk-adjusted incremental cost-effectiveness ratio for the more liberal compared with selective use of DES was $16,000 per TLR avoided, $27,000 per repeat revascularization avoided, and $433,000 per quality-adjusted life-year gained.
The authors write that their findings “suggest that in an era of constrained resources, a more selective approach to DES use would be preferred, at least on economic grounds. With nearly 1 million PCI procedures annually in the United States, adoption of the more selective DES strategy would be expected to result in ~$400 million/y in annual cost savings to the US healthcare system.”
“The bottom-line was that using drug-eluting stents in a relatively unselected way was only resulting in marginal improvement compared to more selective use,” said David Cohen, the senior author of the study, in an AHA press release. “Because of the safety concerns, we were able to verify what many of us had suspected — that using drug-eluting stents in virtually all patients is not that efficient.”
Categories: Uncategorized
Tags: bare metal stents, BMS, DES, drug-eluting stents, Interventional Cardiology
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.
-
Search the Archive
Archives by Date
NEJM — Recent Cardiology Articles- Extended Outcomes of the ADAPT AF-DES Trial November 19, 2026In patients with atrial fibrillation and a stent placed at least 1 year earlier, non–vitamin K antagonist oral anticoagulant monotherapy resulted in fewer net adverse clinical events at 2 years than a NOAC plus clopidogrel.
- Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI November 19, 2026Among patients with STEMI, prasugrel monotherapy initiated before PCI was not noninferior to dual antiplatelet therapy with prasugrel plus aspirin for a composite of death, stroke, or myocardial infarction at 12 months.
- Expanding the Evidence and Indications for Thrombectomy in Ischemic Stroke November 19, 2026In 2015, pivotal randomized, controlled trials established the benefit of endovascular treatment for acute ischemic stroke due to a large-vessel occlusion.1,2 The trials showed a major clinical benefit in patients presenting with relatively standard stroke features: large-vessel occlusion in the anterior circulation; relevant clinical neurologic deficit; short time...
- Too Soon to Say Goodbye — Aspirin at the Door in STEMI November 19, 2026The 19th-century English biologist Thomas H. Huxley once said, “The great tragedy of Science — the slaying of a beautiful hypothesis by an ugly fact.” For as long as many can recall, aspirin has been the first drug administered for the treatment of ST-segment elevation myocardial infarction (STEMI), often in...
- Mechanical Thrombectomy 24 to 72 Hours after Large-Vessel Ischemic Stroke November 19, 2026Among patients with salvageable tissue 24 to 72 hours after stroke, physical function at 90 days was better with thrombectomy than with medical care alone, but intracerebral hemorrhage and death were more common with thrombectomy.
- Extended Outcomes of the ADAPT AF-DES Trial November 19, 2026
-
Tag Cloud
- ACS AF AHA anticoagulation aortic valve replacement apixaban aspirin atrial fibrillation CABG cardiovascular risk cholesterol clopidogrel dabigatran diabetes diet drug-eluting stents epidemiology ESC exercise FDA FDA approvals Fellowship training guidelines HDL heart failure hypertension ICDs MI myocardial infarction obesity PCI Primary PCI risk factors rivaroxaban statins STEMI stents stroke stroke prevention TAVI TAVR type 2 diabetes venous thromboembolism warfarin women
